Cuproptosis-associated CDKN2A is targeted by plicamycin to regulate the microenvironment in patients with head and neck squamous cell carcinoma.
CDKN2A
Cuproptosis
head and neck squamous cell carcinoma (HNSCC)
multiomics
systemic homeostasis
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
09
2022
accepted:
12
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
Head and neck squamous cell carcinoma (HNSCC), the most common malignancy of the head and neck, has an overall 5-year survival rate of <50%. Genes associated with cuproptosis, a newly identified copper-dependent form of cell death, are aberrantly expressed in various tumours. However, their role in HNSCC remains unknown. In this study, bioinformatic analysis revealed that the cuproptosis-related gene CDKN2A was correlated with the malignant behaviour of HNSCC. Kaplan-Meier (KM) curves showed that patients with high CDKN2A expression had a better prognosis. Multiomic analysis revealed that CDKN2A may be associated with cell cycle and immune cell infiltration in the tumour microenvironment and is important for maintaining systemic homeostasis in the body. Furthermore, molecular docking and molecular dynamics simulations suggested strong binding between plicamycin and CDKN2A. And plicamycin inhibits the progression of HNSCC in cellular assays. In conclusion, this study elucidated a potential mechanism of action of the cuproptosis-associated gene CDKN2A in HNSCC and revealed that plicamycin targets CDKN2A to improve the prognosis of patients.
Identifiants
pubmed: 36699463
doi: 10.3389/fgene.2022.1036408
pii: 1036408
pmc: PMC9868476
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1036408Informations de copyright
Copyright © 2023 Fan, Dong, Li and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochim Biophys Acta Mol Cell Res. 2021 Feb;1868(2):118893
pubmed: 33091507
Cancer Immunol Immunother. 2016 May;65(5):575-85
pubmed: 26993499
Front Neurol. 2022 Jun 09;13:909828
pubmed: 35756932
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
pubmed: 20576703
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Front Oncol. 2018 Apr 04;8:95
pubmed: 29670856
J Theor Biol. 2015 Nov 21;385:31-9
pubmed: 26341387
Nucleic Acids Res. 2019 Jan 8;47(D1):D1013-D1017
pubmed: 30364956
Front Aging Neurosci. 2022 Sep 01;14:944195
pubmed: 36118693
J Biomol Struct Dyn. 2015;33(8):1794-804
pubmed: 25297569
Cancer Med. 2020 Sep;9(18):6694-6709
pubmed: 32700817
J Cancer. 2021 May 13;12(14):4148-4171
pubmed: 34093817
Clin Cancer Res. 2020 Jul 1;26(13):3345-3359
pubmed: 32193227
Biomedicines. 2021 Jan 12;9(1):
pubmed: 33445667
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
J Nanosci Nanotechnol. 2021 Feb 1;21(2):1148-1153
pubmed: 33183455
Cell Physiol Biochem. 2018;50(3):868-882
pubmed: 30355925
Trends Biochem Sci. 2019 Nov;44(11):902-913
pubmed: 31301982
Oncogene. 2019 Mar;38(11):1876-1891
pubmed: 30385854
Nucleic Acids Res. 2020 Jan 8;48(D1):D148-D154
pubmed: 31647101
Clin Cancer Res. 2013 Nov 1;19(21):5994-6005
pubmed: 24056784
Front Mol Biosci. 2022 Mar 04;9:841814
pubmed: 35309510
Int J Cancer. 2003 Jan 20;103(3):335-43
pubmed: 12471616
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
Front Aging Neurosci. 2022 Jun 10;14:880794
pubmed: 35754951
J Biol Chem. 2013 Nov 15;288(46):33049-59
pubmed: 24089524
EBioMedicine. 2016 Jun;8:30-39
pubmed: 27428416
Front Aging Neurosci. 2022 Sep 01;14:951197
pubmed: 36118697
Arch Surg. 1999 Dec;134(12):1325-31; discussion 1331-2
pubmed: 10593330
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Neoplasia. 2011 Oct;13(10):947-60
pubmed: 22028620
Oral Oncol. 2021 Nov;122:105545
pubmed: 34598035
Nat Rev Mol Cell Biol. 2008 Sep;9(9):713-24
pubmed: 18719710
Head Neck. 2019 May;41(5):1525-1535
pubmed: 30597654
FEBS Lett. 2008 Oct 15;582(23-24):3257-62
pubmed: 18805416
Neuron. 2018 Sep 19;99(6):1129-1143
pubmed: 30236283
Front Mol Biosci. 2021 Aug 24;8:711227
pubmed: 34504870
Front Genet. 2022 Jul 22;13:942785
pubmed: 35942287
Front Neurol. 2022 Apr 11;13:852013
pubmed: 35481271
PeerJ. 2022 Jan 03;9:e12696
pubmed: 35036166
Front Cell Dev Biol. 2019 Apr 09;7:52
pubmed: 31024913
CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e79
pubmed: 24132163
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Front Pharmacol. 2022 Nov 17;13:1053137
pubmed: 36467072
Breast Cancer Res Treat. 2012 Apr;132(2):545-53
pubmed: 21671016
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cancer Cell. 2018 Jul 9;34(1):56-68.e9
pubmed: 29990501
Nat Rev Immunol. 2017 Dec;17(12):733-745
pubmed: 28920588
Front Aging Neurosci. 2022 May 09;14:860364
pubmed: 35615585
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Am J Physiol Heart Circ Physiol. 2016 Jun 1;310(11):H1735-47
pubmed: 27059076
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
J Immunother Cancer. 2019 Oct 17;7(1):261
pubmed: 31623665
Mol Ther Oncolytics. 2020 Jun 04;18:83-99
pubmed: 32637583
Biosci Rep. 2021 Oct 29;41(10):
pubmed: 34405225
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Clin Cancer Res. 2021 Jan 15;27(2):632-644
pubmed: 33109740
FEBS J. 2015 Jan;282(2):224-58
pubmed: 25393971
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Pancreas. 2021 Sep 1;50(8):1123-1130
pubmed: 34714275
Eur J Surg Oncol. 2001 Jun;27(4):396-403
pubmed: 11417987
Front Oncol. 2022 Jul 06;12:919083
pubmed: 35875087
Trends Biochem Sci. 2013 Jan;38(1):12-9
pubmed: 23218751
Nucleic Acids Res. 2019 Jan 8;47(D1):D1034-D1037
pubmed: 30285109
Ann Oncol. 2017 Oct 1;28(10):2386-2398
pubmed: 28633362
Nat Methods. 2019 Jun;16(6):453-454
pubmed: 31133757
Front Immunol. 2020 Sep 30;11:573920
pubmed: 33101298
Science. 2022 Mar 18;375(6586):1254-1261
pubmed: 35298263
Pharmgenomics Pers Med. 2022 Jul 26;15:733-742
pubmed: 35923305
Dis Markers. 2021 Oct 13;2021:7897994
pubmed: 34691289
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Dis Markers. 2022 Apr 8;2022:4143447
pubmed: 35432628
Oral Oncol. 2006 Aug;42(7):691-7
pubmed: 16527515
Biochemistry. 2011 Jun 28;50(25):5566-82
pubmed: 21619050
Front Neurol. 2022 Jun 20;13:889106
pubmed: 35795796
Front Pharmacol. 2022 Jun 28;13:930041
pubmed: 35837286
Transl Res. 2015 May;165(5):558-77
pubmed: 25468484